<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04973605</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-11417-105</org_study_id>
    <nct_id>NCT04973605</nct_id>
  </id_info>
  <brief_title>Treatment of Relapsed/Refractory Multiple Myeloma With t 11;14 Translocation Using BGB-11417 With Dexamethasone; Also Using BGB-11417 in Combination With Dexamethasone and Carfilzomib.</brief_title>
  <official_title>A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study consists of two parts, a part 1 dose escalation and a part 2 (cohort expansion in&#xD;
      combination with dexamethasone and carfilzomib intravenously across two cohorts)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 16, 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Cycle 1 (Up to 28 days for non-hematologic DLTs and up to 42 days for hematologic DLTs)</time_frame>
    <description>DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5 and will be defined as any of following events: Grade 3 or higher toxicity assessed by the investigator as related to BGB-11417 treatment; and Grade 4 or higher regimen-related organ toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 And 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) with adverse events leading to discontinuation, and AEs graded according NCI-CTCAE Version 5</measure>
    <time_frame>Up to 24 months after last dose of study drug</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 2: Overall response rate (ORR)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Defined as the proportion of patients who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1: Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: Time to reach Cmax (tmax)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: After steady-state: AUC last,ss</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: After steady-state: Cmax, ss</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: After steady-state: trough plasma concentration (Ctrough) ss</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1: After steady-state: time to reach Cmax (tmax,ss)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Very good partial respons VGPR or better response rate</measure>
    <time_frame>Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])</time_frame>
    <description>Defined as the proportion of patients with a documented VGPR or better (including sCR, CR, and VGPR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Complete Response (CR)</measure>
    <time_frame>Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])</time_frame>
    <description>defined as the proportion of patients with a documented CR or sCR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Time to response (TTR) as assessed by investigator</measure>
    <time_frame>Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])</time_frame>
    <description>TTR is defined as the time from start of treatment to first documentation of response of Partial Response (PR) or better</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Duration of response (DOR) as assessed by investigator</measure>
    <time_frame>Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])</time_frame>
    <description>DOR is defined as the time from the date of the first documented response (PR or better) after treatment initiation until the date of first documented disease progression or death due to MM, whichever occurs first. DOR will be analyzed using the same methods as the PFS analysis, but only for patients who have achieved an overall response of at least PR. The distribution of DOR will be summarized by the Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Progression-free survival (PFS) as assessed by investigator</measure>
    <time_frame>Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])</time_frame>
    <description>PFS is defined as time from start of treatment to the first documentation of disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 2: Overall survival (OS) as assessed by investigator</measure>
    <time_frame>Upon study termination (Baseline up to approximately 4 years)</time_frame>
    <description>OS defined as the time from start of treatment to the date of death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Relapsed/Refractory Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Part 1 Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-11417 + dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Dose Finding</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-11417 + dexamethasone + carfilzomib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Cohort Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BGB-11417 + dexamethasone or BGB-11417 + dexamethasone + carfilzomib</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-11417 + Dexamethasone</intervention_name>
    <description>BGB-11417 orally at escalating doses administered in combination with dexamethasone</description>
    <arm_group_label>Part 1 Dose Escalation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGB-11417 + Dexamethasone + Carfilzomib</intervention_name>
    <description>BGB-11417 orally at recommended dose in combination with dexamethasone or dexamethasone and carfilzomib intravenously</description>
    <arm_group_label>Part 1 Dose Finding</arm_group_label>
    <arm_group_label>Part 2 Cohort Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2&#xD;
&#xD;
          2. A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or&#xD;
             urine)&#xD;
&#xD;
          3. Measurable disease defined as:&#xD;
&#xD;
             i. M-spike ≥ 500mg/dL, or&#xD;
&#xD;
             ii. Urine protein M-spike of ≥ 200 mg/day, or&#xD;
&#xD;
             iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio&#xD;
&#xD;
          4. R/R MM is defined as in relapse after ≥ 1 prior therapy, previously exposed to both a&#xD;
             proteosome inhibitor and an IMiD, and in need for systemic treatment or disease that&#xD;
             is unresponsive to therapy. Prior treatment with carfilzomib is allowed but the&#xD;
             patient must have obtained at least a PR and not have had carfilzomib within the past&#xD;
             6 months.&#xD;
&#xD;
             a. induction therapy with consolidation and maintenance, following stem cell&#xD;
             transplant is considered a single line of therapy.&#xD;
&#xD;
             b. Participant has documented relapsed or progressive MM on or after any regimen or&#xD;
             who are refractory to the most recent line of therapy.&#xD;
&#xD;
             i.Relapsed MM is defined as previously treated MM that progresses and requires&#xD;
             initiation of salvage therapy but does not meet the criteria for refractory MM.&#xD;
             ii.Refractory MM is defined as disease that is nonresponsive (failure to achieve&#xD;
             minimal response or development of progressive disease) while on primary or salvage&#xD;
             therapy or progresses within 60 days of last therapy.&#xD;
&#xD;
             c. Participant must have received prior treatment with ≥ 1 but ≤ 5 prior lines of&#xD;
             therapy for MM. A line of therapy consists of greater ≥ 1 complete cycle of a single&#xD;
             agent, a regimen consisting of combination of several drugs, or a planned sequential&#xD;
             therapy of various regimens.&#xD;
&#xD;
          5. Positivity for t(11;14) by local fluorescence in situ hybridization (FISH) testing&#xD;
             fresh bone marrow aspirate sample must be collected at screening and sent to central&#xD;
             laboratory for t(11;14) FISH testing.&#xD;
&#xD;
          6. Confirmation by the central laboratory is required prior to progression to cohort&#xD;
             expansion (Part 2)&#xD;
&#xD;
          7. Adequate organ function defined as:&#xD;
&#xD;
               1. Hemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               2. Platelet count &gt; 100,000/μL&#xD;
&#xD;
               3. Absolute neutrophil count (ANC) &gt; 1000&#xD;
&#xD;
               4. Alanine aminotransferase (ALT) and aspartate aminotransferase &lt; 3 x upper limit&#xD;
                  of normal (ULN) and total bilirubin &lt; 2.0 x ULN&#xD;
&#xD;
               5. Serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 60 mL/min/1.73 m2&#xD;
                  calculated by the MDRD-6 formula&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participant has any of the following conditions:&#xD;
&#xD;
             a. Non secretory MM (Serum free light chains &lt; 10 mg/dL) b. Solitary plasmacytoma c.&#xD;
             Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or &gt; 2.0 x&#xD;
             109/L circulating plasma cells by standard differential) d. Waldenström&#xD;
             macroglobulinemia e. Amyloidosisf. f. Polyneuropathy, organomegaly, endocrinopathy,&#xD;
             monoclonal protein, skin changes (POEMS) syndrome g. Uncontrolled diabetes (HbA1c &gt; 7%&#xD;
             or 53 mmol/mol or requiring insulin at study entry h. Chronic respiratory disease that&#xD;
             requires continuous oxygen&#xD;
&#xD;
          2. Significant cardiovascular disease, including but not limited to:&#xD;
&#xD;
               1. Myocardial infarction ≤ 6 months before screening&#xD;
&#xD;
               2. Unstable angina≤ 3 months before screening&#xD;
&#xD;
               3. New York Heart Association Class III or IV congestive heart failure (see Appendix&#xD;
                  5)&#xD;
&#xD;
               4. History of clinically significant arrhythmias (eg, sustained ventricular&#xD;
                  tachycardia, ventricular fibrillation, or torsades de pointes)&#xD;
&#xD;
               5. Heart rate-corrected QT interval &gt; 480 milliseconds based on Fridericia's formula&#xD;
&#xD;
               6. History of Mobitz II second-degree or third-degree heart block without a&#xD;
                  permanent pacemaker in place&#xD;
&#xD;
               7. Uncontrolled hypertension at screening, defined as systolic blood pressure &gt; 170&#xD;
                  mmHg and diastolic blood pressure &gt; 105 mmHg by ≥ 2 consecutive measurements&#xD;
&#xD;
          3. Known infection with human immunodeficiency virus (HIV)&#xD;
&#xD;
          4. Serologic status reflecting active viral hepatitis B (HBV) or viral hepatitis C (HCV)&#xD;
             infection as follows:&#xD;
&#xD;
             a. Presence of hepatitis B surface antigen (HBsAg) or hepatitis B core antibody&#xD;
             (HBcAb). Patients with presence of HBcAb, but absence of HBsAg, are eligible if HBV&#xD;
             DNA is undetectable (&lt; 20 IU/mL), and if they are willing to undergo monthly&#xD;
             monitoring for HBV reactivation.&#xD;
&#xD;
             b. Presence of HCV antibody. Patients with presence of HCV antibody are eligible if&#xD;
             HCV RNA is undetectable (&lt; 15 IU/mL).&#xD;
&#xD;
          5. Use of the following substances prior to the first dose of study drug:&#xD;
&#xD;
             a. ≤ 45 days prior to the first dose of study drug i. Any biologic and/or&#xD;
             immunologic-based therapy (including, but not limited to, monoclonal antibody therapy&#xD;
             and/or cancer vaccine therapy but not including IMiD agents)&#xD;
&#xD;
             b. ≤ 14 days prior to the first dose of study drug Systemic chemotherapy or&#xD;
             therapeutic radiation therapy (palliative radiation therapy for bone lesions is&#xD;
             acceptable&#xD;
&#xD;
             c. ≤ 7 days prior to the first dose of study drug i. Corticosteroid given with&#xD;
             antineoplastic intent ii. BTK inhibitor, tyrosine kinase inhibitor, or other targeted&#xD;
             small molecule (with 5 half-lives ≤ 7 days) given with antineoplastic intent&#xD;
&#xD;
             Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>BeiGene</last_name>
    <phone>1.877.828.5568</phone>
    <email>clinicaltrials@beigene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. Vincent's Hospital Melbourne</name>
      <address>
        <city>Fitzroy</city>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Middlemore Hospital</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 7, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 22, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

